Advice You - Business

Energy Metals Corporation (TSX: EMC.TO) announced it would commence trading on the Toronto Stock Exchange on Thursday. EMC Chief Executive Paul Matysek’s quote spelled it out, that because of this it would be possible for “… the Company to reach a broader base of

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

individual investors, mutual funds and institutional investors.” In other words, there would be less dependence upon the retail investor, and more reliance on the big funds to pile into EMC shares. Of course, the little guy will join the party as well.

Uranerz Ene

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

rgy (OTC BB: URNZ) issued a few telling news releases, which may explain the direction in which they are heading. On June 5th, the company announced a new Chief Financial Officer. URNZ also announced it had closed a financing, bumping up their cash to just under $1

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

2 million. URNZ Chief Executive Glenn Catchpole told us he hoped to launch his first In Situ Recovery operation for about, or less than, $10 million. This is a good sign. But, it was the next day’s news release which confirmed the earlier news and reinforced where

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

the company is going. The company announced the appointment of three independent directors to its Board. All three were appointed to the audit committee. Two are accountants with impressive track records; the third has an MBA from the University of Western Ontario,

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

one of North America’s top MBA schools. How do we interpret this news release? URNZ probably plans to move from the lowly over the counter bulletin board to a more senior exchange: Amex or NASDAQ Small Cap would be our guess.

What do you do about a company that h

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

asn’t been issuing a flurry of news releases? Take Strathmore Minerals (TSX: STM; Other OTC: STHJF) as an example. There are developments, but the news stream has been fairly quiet. Have they come to a standstill? No, quite the opposite is true.

We did what any in

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

vestor should always do in the absence of major news. We picked up the phone and called their investor relations department. During a brief chat with Craig Christy, the company’s spokesman, we asked about the company’s cash situation. He responded, “We have about C

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

$0.55/share in cash.” Based on Thursday’s closing price, that comes to more than 30 percent of what the market is valuing STM. That’s UP from C$0.37/share earlier this year. STM has plenty of cash and is in excellent financial shape.

We looked through our copy of

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

the Hargreave Hale Report, entitled, “Too Hot to Handle or Just Warming up?” This is a leading British financial institution, based in London. They are a major shareholder in STM, and they have been recommending STM shares. On page 32 of their document, we reviewed

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

a great financial analysis of 33 Canadian and Australian uranium producers and development companies. The bar chart depicted the Uranium Enterprise Value (UREV) per Risk Adjusted pound of U3O8 Reserves and Resources of those thirty-three companies. A horizontal lin

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

e crossed the chart, showing “fair value” of about US$4 million for each company’s UREV per pound adjusted.

It was interesting to study how STM stacked up against many of the most popular uranium companies. Companies, such as Mega Uranium (TSX: MGA) rated at about

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

US$28 million – about 700 percent ABOVE the Hargreave Hale “fair value” analysis. Crosshair Exploration and Mining traded about 500 percent of its fair value. UEX scored about twice above its fair value. Companies such as Uranium Resources, Western Prospector, Pal

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

adin Resources and UrAsia Energy scored at or very near their fair value. Strathmore Minerals had the lowest fair value rating – an absolute steal at about 30 percent of its fair value. About 16 companies traded above their fair value, some very much above the Harg

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

reave Hale fair value analysis. It was enlightening to find Strathmore was in the company of producers such as ERA of Australia, IUC, Uranium One and Denison as an undervalued uranium company. In this case, it was the most undervalued of all 33 companies analyzed b

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

y the City of London financial institution.

We also found out that, a week ago, Strathmore Minerals president David Miller presented at the invitation-only Raymond James In-Situ Leach Uranium Mini-Conference in Toronto and Montreal on June 7th and 8th. You could v

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

isit the Raymond James website for the webcast of David Miller’s presentation, but it has restricted access. Others presenting were Uranium Resources and Energy Metals. We were fortunate to review David Miller’s PowerPoint presentation. One word describes Miller’s

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

presentation: Wow! It really did pack a punch. We heard Raymond James may be releasing these presentations to the public in the near future.

Sometimes, when there is a lack of news, one can learn to dig around and find a company can be doing quite well. In other i

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

nstances, one can study the news releases and try piecing together where the company is heading. We hope this guidance helps you become a more sophisticated investor. We neither recommend stocks nor give buying and selling advice. As always, speculating on natural

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

resource companies can be very risky and suitable only for certain investors. One should always check with their registered financial advisor about what is suitable or not for one’s investment decisions.

COPYRIGHT © 2007 by StockInterview, Inc. ALL RIGHTS RESERVED

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/33635/adviceyou-Inside-A-Companys-News-Release-Part-Two.html">Inside A Company's News Release, Part Two</a>

BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/33635/adviceyou-Inside-A-Companys-News-Release-Part-Two.html]Inside A Company's News Release, Part Two[/url]

Are you a Downey homeowner or a business owner who has recently learned that you have a mold problem? Whether you notice your home's or business's mold on your own or with the assistance of a mold inspector, you will want to get your mold problem taken care of.

Do you have trouble getting prospects to take action on your advertising? Are you confused why prospects that see you advertisement still don't act. Take a moment to learn why your prospects might not be acting and learn and easy step on how to get them to start taking some action.

Tags

Links

Advice You - Inside A Company's News Release, Part Two

Related Articles: